Evidence map›Paper›PMID 19671159›Full record

ArticleBreast cancer research : BCR2009

Dysregulated expression of Fau and MELK is associated with poor prognosis in breast cancer.

Mark R Pickard, Andrew R Green, Ian O Ellis, Carlos Caldas, Vanessa L Hedge, Mirna Mourtada-Maarabouni, Gwyn T Williams

Open access · goldAbstract read
In one paragraph

Article in Breast cancer research : BCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 1 synthesis or guideline pooled it, 163 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Spatiotemporal regulation of MELK during mitosis.Frontiers in cell and developmental biology · 2024
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Targeting Apoptosis in Cancer.Current oncology reports · 2022
    Review
  17. Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells.International journal of molecular sciences · 2021
    Review
  18. Article
  19. Article
  20. Article

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Mark R PickardInstitute for Science and Technology in Medicine and School of Life Sciences, Keele University, Huxley Building, Keele ST5 5BG, UK. m.r.pickard@biol.keele.ac.uk
Andrew R Green
Ian O Ellis
Carlos Caldas
Vanessa L Hedge
Mirna Mourtada-Maarabouni
Gwyn T Williams
Keele University · GBNottingham University Hospitals NHS Trust · GBCancer Research UK · GB

Funding

Biotechnology and Biological Sciences Research CouncilBreast Cancer Now 2005NOV08Wellcome Trust
6 · The paper itself

Abstract

introductionProgrammed cell death through apoptosis plays an essential role in the hormone-regulated physiological turnover of mammary tissue. Failure of this active gene-dependent process is central both to the development of breast cancer and to the appearance of the therapy-resistant cancer cells that produce clinical relapse. Functional expression cloning in two independent laboratories has identified Finkel-Biskis-Reilly murine sarcoma virus-associated ubiquitously expressed gene (Fau) as a novel apoptosis regulator and candidate tumour suppressor. Fau modifies apoptosis-controller Bcl-G, which is also a key target for candidate oncoprotein maternal embryonic leucine zipper kinase (MELK).

methodsWe have used RNA interference to downregulate Fau and Bcl-G expression, both simultaneously and independently, in breast cancer cells in vitro to determine the importance of their roles in apoptosis. Expression of Fau, Bcl-G and MELK was measured by quantitative RT-PCR in breast cancer tissue and in matched breast epithelial tissue from the same patients. Expression data of these genes obtained using microarrays from a separate group of patients were related to patient survival in Kaplan-Meier analyses.

resultssiRNA-mediated downregulation of either Fau or Bcl-G expression inhibited apoptosis, and the inhibition produced by combining the two siRNAs was consistent with control of Bcl-G by Fau. Fau expression is significantly reduced in breast cancer tissue and this reduction is associated with poor patient survival, as predicted for a candidate breast cancer tumour suppressor. In addition, MELK expression is increased in breast cancer tissue and this increase is also associated with poor patient survival, as predicted for a candidate oncogene. Bcl-G expression is reduced in breast cancer tissue but decreased Bcl-G expression showed no correlation with survival, indicating that the most important factors controlling Bcl-G activity are post-translational modification (by Fau and MELK) rather than the rate of transcription of Bcl-G itself.

conclusionsThe combination of in vitro functional studies with the analysis of gene expression in clinical breast cancer samples indicates that three functionally interconnected genes, Fau, Bcl-G and MELK, are crucially important in breast cancer and identifies them as attractive targets for improvements in breast cancer risk prediction, prognosis and therapy.

Indexed as

Gene Expression Regulation, NeoplasticAdenocarcinomaApoptosisBreast NeoplasmsCell Line, TumorEpithelial CellsFemaleGene Knockdown TechniquesGenetic Association StudiesHumansKaplan-Meier EstimateNeoplasm ProteinsPrognosisProtein Serine-Threonine KinasesProto-Oncogene Proteins c-bcl-2Ribosomal ProteinsBCL2L14 protein, humanFAU protein, humanMELK protein, humanNeoplasm ProteinsProtein Serine-Threonine KinasesProto-Oncogene Proteins c-bcl-2Ribosomal ProteinsRNA, Small Interfering

Identifiers

PMID19671159
PMCPMC2750122
OpenAlexW1989368804

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.